GERD

Gastroenterology group updates its position on proton pump inhibitor therapy and the risk of hip fracture.

TORONTO | Sanofi Pasteur has announced the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection.

Check out our review of recent medical stories in the media - Top Story: Booger-eating, nose-picking health benefits: Canadian professor digs in. Read this and

Anti-TNF agents postpone surgery in B.C. study

Experimental device augments the lower esophageal sphincter